v3.26.1
STOCKHOLDERS’ EQUITY
3 Months Ended
Mar. 31, 2026
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 9 – STOCKHOLDERS’ EQUITY

 

The Company has authorized the issuance of up to 100,000,000 shares of common stock, $0.01 par value, and 5,000,000 shares of preferred stock, $0.0001 par value, of which 5,000 shares are designated as Series B Convertible Preferred Stock, 1,610,000 are designated as Series A Preferred Stock and 3,385,000 shares of preferred stock remain undesignated.

 

The Company entered into the ATM Sales Agreement whereby the Company may offer and sell, from time to time, shares of common stock. On June 7, 2024, the Company filed the 2024 Shelf. Under the 2024 Shelf at the time of effectiveness, the Company had the ability to raise up to $150.0 million by selling common stock, preferred stock, debt securities, warrants, and units including $53.3 million of its common stock under the ATM Sales Agreement. As of March 31, 2026, the Company had $44.6 million available under the ATM Sales Agreement.

 

Options and Warrants

 

During the three months ended March 31, 2026, the Company issued an aggregate of 53,000 shares of common stock related to the exercise of options for total proceeds of approximately $81 thousand.

 

Common Stock

 

During the three months ended March 31, 2026, the Company issued an aggregate of 819,691 shares of common stock for service, including vested restricted stock units (“RSUs”).

 

Non-controlling Interest of Discontinued Operations

 

Net income attributed to non-controlling interest of discontinued operations amounted to approximately $532 thousand for the three months ended March 31, 2025. During the three months ended March 31, 2025, the Company paid distributions to non-controlling interest holders of discontinued operations of approximately $36 thousand.

 

Dividends

 

The Company pays cumulative dividends on its Series A Preferred Stock, in the amount of $2.21875 per share each year, which is equivalent to 8.875% of the $25.00 liquidation preference per share. Dividends on the Series A Preferred Stock are payable quarterly in arrears, on or about the 15th day of January, April, July, and October of each year. The dividends are included in the Company’s results of operations for the three months ended March 31, 2026 and 2025. Dividends declared and paid on the Series A Preferred Stock during the three months ended March 31, 2026 and 2025 are as follows:

 

Declaration Date  Record Date  Payment Date
March 24, 2026  April 3, 2026  April 15, 2026
March 25, 2025  April 4, 2025  April 15, 2025

 

 

Stock Options

 

On January 8, 2021, the Company approved the Company’s 2020 Equity and Incentive Plan (the “2020 Plan”). Approval of the 2020 Plan was included as Proposal 1 in the Company’s definitive proxy statement for its Special Meeting of Stockholders filed with the Securities and Exchange Commission on December 7, 2020. The 2020 Plan is administered by the Compensation Committee of the Board of Directors (the “Board”) and initially provided for the issuance of up to 1,500,000 shares of Common Stock. The number of shares of Common Stock available for issuance under the 2020 Plan automatically increases by 150,000 shares of Common Stock on January 1st of each year, for a period of not more than ten years, commencing on January 1, 2021 and ending on (and including) January 1, 2030. Awards under the 2020 Plan can be granted in the form of stock options, non-qualified and incentive options, stock appreciation rights, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”).

 

On June 24, 2021, at the Annual Meeting of Stockholders, the stockholders of the Company approved the amendment and restatement to the 2020 Plan, which amended the 2020 Plan to increase the maximum number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares. On June 16, 2022, at the Annual Meeting of Stockholders, the stockholders of the Company approved the second amendment and restatement of the 2020 Plan, which amended the 2020 Plan to increase the maximum number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares. On June 14, 2024, at the Annual Meeting of Stockholders, the stockholders of the Company approved the third amendment and restatement to the 2020 Plan (the “Amended 2020 Plan”), which further amended the 2020 Plan by increasing the maximum number of shares of the Company’s common stock available for issuance under the Amended 2020 Plan by 3,000,000 shares.

 

As of March 31, 2026, the Amended 2020 Plan provided for the issuance of up to 8,400,000 shares of Common Stock. Remaining authorization under the Amended 2020 Plan was 996,818 shares as of March 31, 2026.

 

The forms of award agreements to be used in connection with awards made under the Amended 2020 Plan to the Company’s executive officers and non-employee directors are:

 

Form of Non-Qualified Option Agreement (Non-Employee Director Awards)
Form of Non-Qualified Option Agreement (Employee Awards); and
Form of Restricted Stock Award Agreement.

 

Previously, the Company had granted service-based stock options and performance-based stock options separate from the Amended 2020 Plan. The following is a summary of outstanding options activity under our Amended 2020 Plan for the three months ended March 31, 2026:

 

  

Options

Outstanding

Number of

Shares

  

Exercise Price

per Share

  

Weighted

Average

Remaining

Contractual

Life

  

Weighted

Average

Exercise Price

per Share

 
Balance at December 31, 2025   229,250   $1.84 13.74    2.43 years   $7.94 
Granted   -    -    -    - 
Exercised   (3,000)   1.84    1.82 years    1.84 
Cancelled/Forfeited/Expired   -    -    -    - 
Balance at March 31, 2026   226,250   $1.8913.74    2.19 years   $8.02 
                     
Exercisable at December 31, 2025   229,250   $1.8413.74    2.43 years   $7.94 
Exercisable at March 31, 2026   226,250   $1.8913.74    2.19 years   $8.02 

 

Total compensation expense for the Amended 2020 Plan options above was approximately $0 and $7 thousand for the three months ended March 31, 2026 and 2025, respectively, with no unamortized expense remaining as of March 31, 2026. During the three months ended March 31, 2026, 3,000 options were exercised and total proceeds received were approximately $6 thousand. As of March 31, 2026, aggregate intrinsic value of vested service-based options outstanding was $67 thousand.

 

 

The following is a summary of outstanding service-based options activity (prior to the establishment of our Amended 2020 Plan above) for the three months ended March 31, 2026:

 

  

Options

Outstanding

Number of

Shares

  

Exercise Price

per Share

  

Weighted

Average

Remaining

Contractual

Life

  

Weighted

Average

Exercise Price

per Share

 
Balance at December 31, 2025   390,333   $1.0011.98    2.28 years   $4.03 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled/Forfeited/Expired   (2,500)   11.98    -    11.98 
Balance at March 31, 2026   387,833   $1.0011.56    2.05 years   $3.97 
                     
Exercisable December 31, 2025   390,333   $1.0011.98    2.28 years   $4.03 
Exercisable at March 31, 2026   387,833   $1.0011.56    2.05 years   $3.97 

 

Total compensation expense under the above service-based option plan was $0 and $145 thousand for the three months ended March 31, 2026 and 2025, respectively, with no unamortized expense remaining as of March 31, 2026. As of March 31, 2026, aggregate intrinsic value of vested service-based options outstanding was $430 thousand.

 

The following is a summary of outstanding performance-based options activity for the three months ended March 31, 2026:

 

  

Options

Outstanding

Number of

Shares

  

Exercise Price

per Share

  

Weighted

Average

Remaining

Contractual

Life

  

Weighted

Average

Exercise Price

per Share

 
Balance at December 31, 2025   80,000   $1.251.75    1.62 years   $1.59 
Granted   -    -    -    - 
Exercised   (50,000)   1.251.75    1.38 years    1.50 
Balance at March 31, 2026   30,000   $1.75    1.38 years   $1.75 
                     
Exercisable December 31, 2025   65,000   $1.251.75    1.59 years   $1.56 
Exercisable at March 31, 2026   15,000   $1.75    1.25 years   $1.75 

 

Total compensation expense under the above performance-based options plan was $0 for both the three months ended March 31, 2026 and 2025. During the three months ended March 31, 2026, 50,000 options were exercised and total proceeds received were approximately $75 thousand. As of March 31, 2026, aggregate intrinsic value of vested performance options outstanding was $56 thousand.

 

RSUs and RSAs (under our Amended 2020 Plan)

 

The following is a summary of unvested RSUs and RSAs activity under our Amended 2020 Plan for the three months ended March 31, 2026:

 

   

RSUs and RSAs

Unvested

Number of Shares

 
Balance at December 31, 2025    2,274,587 
Granted    388,000 
Vested    (566,000)
Cancelled/Forfeited    (260,584)
Balance at March 31, 2026    1,836,003 

 

The total fair value of the 388,000 RSUs and RSAs granted was approximately $1.5 million which was determined using the fair value of the quoted market price on the date of grant. Total compensation expense under the Amended 2020 Plan RSUs and RSAs above was approximately $1.4 million and $2.4 million for the three months ended March 31, 2026 and 2025, respectively, with unamortized expense remaining of approximately $4.9 million as of March 31, 2026. During the three months ended March 31, 2026, a total of 819,691 shares of common stock were issued in connection with RSUs and RSAs, including: (i) 566,000 shares issued upon vesting of awards during the current period, and (ii) 253,691 shares issued upon settlement of awards that had vested in prior periods.

 

 

RSUs and RSAs (outside of our Amended 2020 Plan)

 

The following is a summary of unvested RSUs and RSAs activity (outside of our Amended 2020 Plan) for the three months ended March 31, 2026:

 

  

RSUs and RSAs

Unvested

Number of Shares

 
Balance at December 31, 2025   100,000 
Granted   - 
Vested   - 
Balance at March 31, 2026   100,000 

 

Total compensation expense for RSUs and RSAs outside of the Amended 2020 Plan was $0 for both the three months ended March 31, 2026 and 2025, with no unamortized expense remaining as of March 31, 2026.

 

Warrants

 

The following is a summary of outstanding and exercisable warrants activity during the three months ended March 31, 2026:

 

  

Warrants

Outstanding

Number of

Shares

  

Exercise Price

per Share

  

Weighted

Average

Remaining

Contractual

Life

  

Weighted

Average

Exercise Price

per Share

 
Balance at December 31, 2025   1,172,877   $1.2412.00    1.67 years   $5.88 
Exercised   -    -    -    - 
Cancelled/Forfeited/Expired   -    -    -    - 
Balance at March 31, 2026   1,172,877   $1.2412.00    1.42 years   $5.88 
                     
Exercisable December 31, 2025   1,172,877   $1.2412.00    1.67 years   $5.88 
Exercisable March 31, 2026   1,172,877   $1.2412.00    1.42 years   $5.88 

 

Total compensation expense on the above warrants for services was $0 for both the three months ended March 31, 2026 and 2025, with no unamortized expense remaining as of March 31, 2026.

 

Stock-based Compensation

 

The total stock-based compensation expense related to common stock issued for services, service-based stock options, performance-based stock options, warrants and RSUs, and RSAs amounted to $1.4 million and $2.5 million for the three months ended March 31, 2026 and 2025, respectively. Such amounts are included in general and administrative expenses in the unaudited consolidated statements of operations. Unamortized expense remaining related to RSUs was $4.9 million as of March 31, 2026, which is expected to be recognized through 2029.